They can encode full-length tumor antigens, allowing for the presentation of multiple epitopes via MHC class I and II pathways, thereby generating a broader and more robust CD4+ and CD8+ T cell response (Sahin et al., 2014). This evidence concerns the gene CD8A and neoplasm.